Which combination of medications is recommended for a patient undergoing primary percutaneous coronary intervention (PCI) with ST-elevation myocardial infarction?

For a patient undergoing primary percutaneous coronary intervention (PCI) with ST-elevation myocardial infarction (STEMI), it is essential to use a combination of medications that effectively address both antiplatelet and anticoagulation needs to reduce the risk of thrombotic events and improve outcomes.

The correct answer highlights that a regimen including aspirin, a P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor), and an anticoagulant is recommended. This combination enhances the overall antithrombotic effect during the acute phase of STEMI management. Aspirin serves as a cornerstone antiplatelet therapy, while P2Y12 inhibitors further inhibit platelet aggregation. The use of an anticoagulant is critical in this setting, as it helps to prevent further thrombus formation and supports the efficacy of the PCI procedure.

This triad of medications ensures comprehensive antithrombotic therapy, which is crucial in reducing myocardial damage and improving clinical outcomes in STEMI patients. It aligns with current clinical guidelines, which emphasize dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) combined with an anticoagulant during the acute treatment phase of STEMI, especially when PCI is